Great breakthrough in cancer research

News source: 
RCT

Researchers have revealed a new cancer drug for patients with HER2- positive metastatic breast cancer at the European Multidisciplinary Cancer Congress 2011 in Stockholm. T-DM1, trastuzumab emtansine, is a cytotoxic agent linked to an antibody, that specifically targets HER2- positive metastatic cancer cells. Patients who have received this drug during the phase II- trials had significantly fewer side effects and had a longer time to live without their disease worsening in comparison to patients who have received standard chemotherapy treatment.

For more information, consult the ESMO (European Society for Medical Oncology) website